Therapeutic vaccination for chronic hepatitis B virus infection in Africa

Completed

• Conditions: Hepatitis B virus; Infections and Infestations

• Registration Number: ISRCTN67270384
• Lead Sponsor: niversity of Oxford (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11-23
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 77

Inclusion Criteria

1. Chronic HBV infection
2. Male, 15 to 25 years
3. No evidence of liver inflammation or liver dysfunction

Exclusion Criteria

1. Egg allergy
2. Serious disorder of any body system

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Local tolerogenicity<br>2. Adverse events<br>3. Cellular immune responses to overlapping peptides of Hepatitis B surface protein<br>4. HBV serology<br>5. Anti-HBs levels, surface antigen<br>6. 'e' antigen<br>7. HBV viral load

Secondary Outcome Measures

Name	Time	Method
o secondary outcome measures